<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/Pharma1Dec1125-shutterstock_2709265951-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/Pharma1Dec1125-shutterstock_2709265951-430x241.jpg"/></p>
<p>LNK01006 是一種新一代中樞神經系統穿透藥物。來源：MY STOCKERS/Shutterstock.com。</p>
<p>Formation Bio 已獲得 LNK01006 的全球權利，除大中華區外，該藥物是一種高度選擇性的酪氨酸激酶 2 (TYK2) 抑制劑，來自 Lynk Pharmaceuticals。</p>
<p>這款新一代中樞神經系統穿透藥物將由 Formation 新成立的子公司 Bleecker Bio 開發。</p>
<h3>深入瞭解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>報告</p>
<h4>NPVM: Aptose Biosciences Inc 的 Tuspetinib</h4>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>報告</p>
<h4>NPVM: Kymera Therapeutics Inc 的 KT-413</h4>
<h5>深入瞭解 GlobalData</h5>
<p>商業智能的黃金標準。</p>
<p>瞭解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>發現高效的 B2B 營銷</h4>
<p>結合商業智能和編輯卓越，接觸到 36 個領先媒體平台上的專業人士。</p>
<p>瞭解更多</p>
<p>Lynk Pharmaceuticals 將獲得 Bleecker 的少數股權，以及一次性付款和可能達到 6.05 億美元的里程碑付款。</p>
<p>該交易還包括未來資產銷售的分級版税。</p>
<p>總部位於美國的投資基金 Pacific Bridge 作為 Bleecker 的少數聯合投資者參與其中。</p>
<p>該資產最近獲得了美國食品和藥物管理局 (FDA) 的研究新藥 (IND) 批准，允許在美國開始首次人體試驗。</p>
<p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData 戰略情報</p>
<h1>美國關税正在變化 - 你會反應還是預見？</h1>
<p>不要讓政策變化讓你措手不及。通過實時數據和專家分析保持主動。</p>
<p>來自 GlobalData</p>
<p>瞭解更多關於戰略情報的信息</p>
<p>Formation 打算在 2026 年上半年開始 I 期臨牀試驗，作為其擴展臨牀階段資產組合戰略的一部分。</p>
<p>LNK01006 提供對 TYK2 介導的細胞因子信號傳導的選擇性抑制，並具有針對中樞免疫系統調節的藥理特徵。</p>
<p>該療法的藥理特徵可能允許探索在中樞或局部免疫通路被認為重要的適應症。</p>
<p>Formation Bio 首席商務官 David Steinberg 表示：“該資產代表了我們所稱的 ‘已知新’ 戰略的一個典範，即將經過驗證的機制應用於高未滿足需求的新領域。</p>
<p>“利用世界級的人類專業知識、強大的臨牀數據集和自主研發的先進 AI 工具，我們圍繞臨牀風險降低的資產類別的新療法應用開發了深厚的假設。”</p>
<p>Lynk Pharmaceuticals 是一家專注於發現和開發免疫學和炎症疾病藥物的臨牀階段公司。</p>
<p>Lynk Pharmaceuticals 首席執行官趙奎萬表示：“我們很高興與 Formation Bio 合作，將 LNK01006 推進臨牀。</p>
<p>“Formation 經驗豐富的臨牀開發團隊和 AI 驅動的能力提供了將該化合物的科學潛力轉化為有意義的患者影響的理想環境。”</p>
<h2>製藥技術卓越獎 - 提名已關閉</h2>
<p>提名現已關閉，感謝所有參與的組織 - 你們的反應非常出色，展示了卓越的創新、領導力和影響力。</p>
<p><strong>行動中的卓越</strong></p>
<p>Imagene 的 腫瘤智能 (OI) 套件 獲得了精準腫瘤學創新獎，因其改變了製藥公司設計和運行腫瘤試驗的方式。從 AI 驅動的生物標誌物發現到更智能的患者分層，看看 Imagene 如何在癌症藥物開發中縮短時間、降低成本和風險。</p>
<p>發現影響</p>

<p>Formation Bio 已獲得 Lynk Pharma 的 TYK2 抑制劑 LNK01006 的全球權利，但不包括大中華區。該藥物具有中樞神經系統穿透能力，將由 Formation 的子公司 Bleecker Bio 開發。Lynk 將獲得 Bleecker 的少數股權、最高達 6.05 億美元的預付款和里程碑付款，以及分級版税。該藥物已獲得 FDA 的 IND 批准，可以在美國進行臨牀試驗。Formation 計劃於 2026 年進行 I 期臨牀試驗，旨在擴展其臨牀階段的產品組合。Lynk 專注於免疫學和炎症性疾病</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/Pharma1Dec1125-shutterstock_2709265951-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/Pharma1Dec1125-shutterstock_2709265951-430x241.jpg"/></p>
<p>LNK01006 is a next-generation CNS-penetrant. Credit: MY STOCKERS/Shutterstock.com.</p>
<div class="lb-trans"><p>LNK01006 是一種新一代中樞神經系統穿透藥物。來源：MY STOCKERS/Shutterstock.com。</p>
</div><p>Formation Bio has acquired the global rights, excluding in Greater China, to LNK01006, a highly selective tyrosine kinase 2 (TYK2) inhibitor from Lynk Pharmaceuticals.</p>
<div class="lb-trans"><p>Formation Bio 已獲得 LNK01006 的全球權利，除大中華區外，該藥物是一種高度選擇性的酪氨酸激酶 2 (TYK2) 抑制劑，來自 Lynk Pharmaceuticals。</p>
</div><p>This next-generation central nervous system (CNS)-penetrant will be developed by Bleecker Bio, a newly established subsidiary of Formation.</p>
<div class="lb-trans"><p>這款新一代中樞神經系統穿透藥物將由 Formation 新成立的子公司 Bleecker Bio 開發。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入瞭解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>報告</p>
</div><h4>NPVM: Aptose Biosciences Inc's Tuspetinib</h4>
<div class="lb-trans"><h4>NPVM: Aptose Biosciences Inc 的 Tuspetinib</h4>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>報告</p>
</div><h4>NPVM: Kymera Therapeutics Inc's KT-413</h4>
<div class="lb-trans"><h4>NPVM: Kymera Therapeutics Inc 的 KT-413</h4>
</div><h5>Go deeper with GlobalData</h5>
<div class="lb-trans"><h5>深入瞭解 GlobalData</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商業智能的黃金標準。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>瞭解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>發現高效的 B2B 營銷</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>結合商業智能和編輯卓越，接觸到 36 個領先媒體平台上的專業人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>瞭解更多</p>
</div><p>Lynk Pharmaceuticals will obtain a minority equity stake in Bleecker, along with an upfront payment and potential milestone payments that could reach $605m.</p>
<div class="lb-trans"><p>Lynk Pharmaceuticals 將獲得 Bleecker 的少數股權，以及一次性付款和可能達到 6.05 億美元的里程碑付款。</p>
</div><p>The deal also includes tiered royalties on any future sales of the asset.</p>
<div class="lb-trans"><p>該交易還包括未來資產銷售的分級版税。</p>
</div><p>US-based investment fund Pacific Bridge is participating as a minority joint investor in Bleecker.</p>
<div class="lb-trans"><p>總部位於美國的投資基金 Pacific Bridge 作為 Bleecker 的少數聯合投資者參與其中。</p>
</div><p>The asset recently received US Food and Drug Administration (FDA) investigational new drug (IND) clearance, allowing the commencement of first-in-human trials in the US.</p>
<div class="lb-trans"><p>該資產最近獲得了美國食品和藥物管理局 (FDA) 的研究新藥 (IND) 批准，允許在美國開始首次人體試驗。</p>
</div><p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData Strategic Intelligence</p>
<div class="lb-trans"><p>GlobalData 戰略情報</p>
</div><h1>US Tariffs are shifting - will you react or anticipate?</h1>
<div class="lb-trans"><h1>美國關税正在變化 - 你會反應還是預見？</h1>
</div><p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
<div class="lb-trans"><p>不要讓政策變化讓你措手不及。通過實時數據和專家分析保持主動。</p>
</div><p>By GlobalData</p>
<div class="lb-trans"><p>來自 GlobalData</p>
</div><p>Learn more about Strategic Intelligence</p>
<div class="lb-trans"><p>瞭解更多關於戰略情報的信息</p>
</div><p>Formation intends to begin a Phase I trial in the first half of 2026, as part of its strategy to expand its portfolio of clinical-stage assets.</p>
<div class="lb-trans"><p>Formation 打算在 2026 年上半年開始 I 期臨牀試驗，作為其擴展臨牀階段資產組合戰略的一部分。</p>
</div><p>LNK01006 offers selective inhibition of TYK2-mediated cytokine signalling and features a pharmacological profile tailored for central immune system modulation.</p>
<div class="lb-trans"><p>LNK01006 提供對 TYK2 介導的細胞因子信號傳導的選擇性抑制，並具有針對中樞免疫系統調節的藥理特徵。</p>
</div><p>The pharmacologic profile of the therapy may allow for the exploration of indications where central or compartmentalised immune pathways are considered important.</p>
<div class="lb-trans"><p>該療法的藥理特徵可能允許探索在中樞或局部免疫通路被認為重要的適應症。</p>
</div><p>Formation Bio chief business officer David Steinberg stated: “This asset represents a prime example of what we call our ‘Known In New’ strategy of applying validated mechanisms to novel areas of high unmet need.</p>
<div class="lb-trans"><p>Formation Bio 首席商務官 David Steinberg 表示：“該資產代表了我們所稱的 ‘已知新’ 戰略的一個典範，即將經過驗證的機制應用於高未滿足需求的新領域。</p>
</div><p>“Leveraging world class human expertise, robust clinical data sets and homegrown, state-of the-art AI tools, we’ve developed deeply grounded hypotheses around novel therapeutic applications of clinically de-risked asset classes.”</p>
<div class="lb-trans"><p>“利用世界級的人類專業知識、強大的臨牀數據集和自主研發的先進 AI 工具，我們圍繞臨牀風險降低的資產類別的新療法應用開發了深厚的假設。”</p>
</div><p>Lynk Pharmaceuticals is a clinical-stage company focused on discovering and developing medicines for immunology and inflammatory diseases.</p>
<div class="lb-trans"><p>Lynk Pharmaceuticals 是一家專注於發現和開發免疫學和炎症疾病藥物的臨牀階段公司。</p>
</div><p>Lynk Pharmaceuticals CEO Zhao-Kui (ZK) Wan stated: “We are excited to partner with Formation Bio to advance LNK01006 into the clinic.</p>
<div class="lb-trans"><p>Lynk Pharmaceuticals 首席執行官趙奎萬表示：“我們很高興與 Formation Bio 合作，將 LNK01006 推進臨牀。</p>
</div><p>“Formation’s experienced clinical development team and AI-enabled capabilities provide the ideal environment to translate this compound’s scientific potential into meaningful patient impact.”</p>
<div class="lb-trans"><p>“Formation 經驗豐富的臨牀開發團隊和 AI 驅動的能力提供了將該化合物的科學潛力轉化為有意義的患者影響的理想環境。”</p>
</div><h2>Pharmaceutical Technology Excellence Awards - Nominations Closed</h2>
<div class="lb-trans"><h2>製藥技術卓越獎 - 提名已關閉</h2>
</div><p>Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.</p>
<div class="lb-trans"><p>提名現已關閉，感謝所有參與的組織 - 你們的反應非常出色，展示了卓越的創新、領導力和影響力。</p>
</div><p><strong>Excellence in Action</strong></p>
<div class="lb-trans"><p><strong>行動中的卓越</strong></p>
</div><p>Imagene’s Oncology Intelligence (OI) Suite has won the Innovation Award for Precision Oncology, for transforming how pharma designs and runs oncology trials. From AI-driven biomarker discovery to smarter patient stratification, see how Imagene is cutting time, cost and risk in cancer drug development.</p>
<div class="lb-trans"><p>Imagene 的 腫瘤智能 (OI) 套件 獲得了精準腫瘤學創新獎，因其改變了製藥公司設計和運行腫瘤試驗的方式。從 AI 驅動的生物標誌物發現到更智能的患者分層，看看 Imagene 如何在癌症藥物開發中縮短時間、降低成本和風險。</p>
</div><p>Discover the Impact</p>
<div class="lb-trans"><p>發現影響</p>
</div>

Formation Bio 獲得了 Lynk Pharma 的 TYK2 抑制劑的全球使用權